Glulisine + Lantus in Type I Patients

NCT ID: NCT00545337

Last Updated: 2009-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2005-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR 1964) in subjects with type I diabetes mellitus

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insuline glulisine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* type I diabetes mellitus (onset of diabetes under the age of 40),
* an HbA1c range of \>6.5 - \<11%,
* and on multiple injection regimen (more than 1 year of continuous insulin treatment),
* body mass index \<35.

Exclusion Criteria

* Active proliferative diabetic retinopathy,
* Diabetes other than type I diabetes mellitus,
* Pancreatectomised subjects,
* Subjects who have undergone pancreas and or islet cell transplants,
* Requiring treatment with not permited drugs during the study,
* Previous treatment (in the period not less than 1 month before the beginning of the trial) with insulin glargine,
* Hypersensitivity to insulin,
* Major systemic diseases,
* Impaired hepatic or renal function

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

sanofi-aventis

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Volodymyr Moshchych

Role: STUDY_DIRECTOR

Sanofi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sanofi-Aventis

Kiev, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Ukraine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HMR1964A_3505UA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glulisine Pre- and Postmeal
NCT00290043 COMPLETED PHASE1
Insulin Glargine in Type 2 Diabetes
NCT00268645 COMPLETED PHASE4
20 Week Bridging Study in Type II DM
NCT00563225 COMPLETED PHASE3